Mycoplasma Removal Agent

100% Secure


Mycoplasma Removal Agent

Mycoplasma removal agent is used to remove mycoplasma from infected cell cultures. It shows strong anti-mycoplasma activity against many types of mycoplasma including Mycoplasma orale, M. arginini, M. hyorhinis and Acholeplasma laidlawii.

Product Type
Accessory Reagent
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
BUF035 TC 5 ml

Product Details

Intended Use
MRA is very effective at removing mycoplasma from infected cell cultures. It shows strong anti-mycoplasma activity against many types of mycoplasma including Mycoplasma orale, M. arginini, M. hyorhinis and Acholeplasma laidlawii.

MRA is also suitable for use after the removal of mycoplasma, to prevent recontamination of the culture with the original mycoplasma, at preventative doses.

This product can also be used to prevent initial infection of cells in culture by mycoplasma.

MRA is non toxic, and will not interfere with the viability or function of cells in culture. It should be emphasised that MRA should not be used as a substitute for good cell culture techniques.
Approx. Protein Concentrations
50ug/ml

Storage Information

Storage
Store at room temperature.
This product should be stored undiluted.
This product is photosensitive and should be protected from light.
Shelf Life
5 years from date of despatch.

More Information

Regulatory
For research purposes only

Applications of Mycoplasma Removal Agent

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Tissue Culture
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Instructions For Use
MRA is very easy to use, simply requiring incubation for a week after addition to cell cultures contaminated by mycoplasma.

Indications for Use:

1. Add MRA to cell cultures contaminated by mycoplasma at a concentration of 0.5 μg/ml and incubate for a week.

2. For media replacement or culture transfer (passage), use a medium containing MRA at this same concentration.

3. Transfer the cell cultures several times without MRA and confirm that regrowth of the contaminating mycoplasma has not occurred.

If there is a concern about the presence of mycoplasma in serum or trypsin, MRA can be added to the media at a concentration of 0.5 μg/ml to prevent contamination of the cell cultures exposed to these products.

N.B. The recommended concentration for use is 0.5 μg/ml. The MRA concentration may be raised up to 1 μg/ml only when the recommended concentration is ineffective in removing the mycoplasma.

The cytotoxicity of MRA is low and cell toxicity is rare when used at the recommended concentration. For specific function of any cell, however, it is recommended that the retention of desired cellular characteristics be confirmed after treatment.
Please follow this link to view Sample Data.

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Mouse Monoclonal Antibody Isotyping Test Kit MMT1 10 Tests IS
Proteus Protein A MIDI Purification Kit PUR003 4 Units PP
Proteus Protein A Mini Purification Kit PUR008 16 Units PP
Proteus Protein G MIDI Purification Kit PUR012 4 Units PP
Proteus Protein G Mini Purification Kit PUR016 16 Units PP
Rat Monoclonal Antibody Isotyping Test Kit RMT1 10 Tests IS

Product Specific References

References for Mycoplasma Removal Agent

  1. Nakai, N. et al. (2000) Detection and elimination of contaminating microorganisms in transplantable tumors and cell lines.
    Exp Anim. 49 (4): 309-13.
  2. Ndungu, F.M. et al. (2006) CD4 T cells from malaria-nonexposed individuals respond to the CD36-Binding Domain of Plasmodium falciparum erythrocyte membrane protein-1 via an MHC class II-TCR-independent pathway.
    J Immunol. 176 (9): 5504-12.
  3. Chang, M.C. et al. (2015) N-Farnesyloxy-norcantharimide and N-farnesyl-norcantharimide inhibit the progression of leukemia and increase survival days in a syngeneic mouse leukemia model.
    Anticancer Drugs. 26 (5): 508-17.
  4. Entrican, G. et al. (2009) Growing Hybridomas
    The Protein Protocols Handbook: 1887-99.
  5. Molla Kazemiha, V. et al. (2009) PCR-based detection and eradication of mycoplasmal infections from various mammalian cell lines: a local experience.
    Cytotechnology. 61 (3): 117-24.
  6. Molla Kazemiha, V. et al. (2011) Efficiency of Plasmocin™ on various mammalian cell lines infected by mollicutes in comparison with commonly used antibiotics in cell culture: a local experience.
    Cytotechnology. 63 (6): 609-20.